# Targeting ATR in Soft-tissue Sarcomas

> **NCT04807816** · PHASE2 · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 58 (actual)

## Conditions studied

- Leiomyosarcoma, Adult

## Interventions

- **DRUG:** Association of berzosertib with gemcitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04807816
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-09
- **Primary completion:** 2024-09-29
- **Final completion:** 2026-04-21
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807816, "Targeting ATR in Soft-tissue Sarcomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04807816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*